Business Wire

Workiva Wins DevOps Excellence Award in London

Del

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, today announced that its Wdesk platform was named the Best Software-Defined Product, last night at Computing's DevOps Excellence Awards dinner.

The Computing DevOps Excellence Awards recognize outstanding achievement from organisations, personalities and solutions operating within the DevOps industry. Winners were selected on their superior functionality, level of ability to modernize business processes, positive customer feedback and a strong return on investment.

“We are proud to win this prestigious award,” said Marty Vanderploeg, CEO of Workiva. “As the global leader in connected reporting, XBRL and Inline XBRL, our Wdesk platform helps customers all over the world consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders.”

XBRL (eXtensible Business Reporting Language) standardizes how regulators, investors and companies analyze and consume financial data. Inline XBRL creates a single, standardized, machine-readable report that is integrated within companies’ human-readable HTML filings.

Workiva, which was one of the first companies to be certified by XBRL International, has been on the forefront of helping Foreign Private Issuers use XBRL tags in their U.S. Securities and Exchange Commission (SEC) filings.

European companies are now adopting Wdesk to comply with the European Securities and Markets Authority's mandate for Inline XBRL for its European Single Electronic Format (ESEF) taxonomy. More than 5,000 EU issuers will be required to use this taxonomy for their annual financial reports, ending on or after January 1, 2020.

Multinational companies are also using Wdesk to improve efficiency and transparency in global statutory reporting, which is a complex and painful process for reporting information to government agencies in compliance with each jurisdictions’ local GAAP requirements. Wdesk users are able to connect their data, people and processes with built-in workflow, tasking and a full audit trail.

Wdesk is the only cloud platform that provides data assurance throughout the entire reporting process — from ERP transactional data to final reports,” said Vanderploeg. “Our Wdesk platform will continue to be a driving force in transforming financial reporting throughout the world.”

See the full list of DevOps Excellence Award winners here.

About Workiva
Workiva, the leading cloud provider of connected data, reporting and compliance solutions, is used by thousands of enterprises across 180 countries, including more than 75 percent of Fortune 500® companies, and by government agencies. Our customers have linked over five billion data elements to trust their data, reduce risk and save time. For more information about Workiva (NYSE:WK), please visit workiva.com.

Read the Workiva blog: www.workiva.com/blog
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva/
Follow Workiva on Twitter: www.twitter.com/Workiva

Claim not confirmed by FORTUNE or Fortune Media IP Limited. FORTUNE® and FORTUNE 500® are registered trademarks of Fortune Media IP Limited and are used under license. FORTUNE and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Workiva Inc.

Contact information

Media:
Kevin McCarthy
Workiva Inc.
press@workiva.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation18.4.2019 10:00:00 CESTPressemelding

Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005161/en/ Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to pro

Racketeering Lawsuit Filed by Boies Schiller Flexner LLP Alleges Czech Oligarch Defrauds US Hedge Fund and Former Partner Out of Over $1 Billion18.4.2019 07:41:00 CESTPressemelding

New York hedge fund, Kingstown Capital Management L.P, and other plaintiffs filed a lawsuit on 10 April 2019 in the Southern District of New York against Radovan Vitek, a Czech real estate mogul with business interests throughout Europe, whose fortune Forbes magazine estimates at $3.5 billion. Represented by litigation powerhouse Boies Schiller Flexner LLP, the hedge fund Kingstown Capital Management L.P and Czech investment firm Investhold Ltd allege that Vitek ran an elaborate criminal enterprise that defrauded the plaintiffs out of more than US $1 billion. According to the complaint, Berlin’s largest commercial real estate landlord, Vitek engaged in racketeering activity including wire fraud, mail fraud, money laundering, and other crimes and amassed his wealth at the expense of the plaintiffs, according to the complaint. His commercial interests span multiple jurisdictions including the Czech Republic, Switzerland, Luxembourg, Germany, Croatia and UK. The complaint alleges that Vit

MHI Thermal Systems Develops Demonstration Unit of the World’s First Small-Capacity Residential Air-Conditioner Adopting the Low-GWP R454C Refrigerant18.4.2019 07:21:00 CESTPressemelding

Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/ Residential type

Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System18.4.2019 07:00:00 CESTPressemelding

Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005130/en/ ThinPrep Genesis processor (Photo: Business Wire) The Genesis processor is the latest extension of the ThinPrep portfolio, which revolutionized and increased the accuracy of cervical cancer screening with the first liquid-based Pap test in 1996. Hologic launched an updated ThinPrep® 2000 processor in 2017 and received FDA approval in 2018 for the ThinPrep® Integrated Imager, which guides cytotechnologists to ar

Ipsen Completes Acquisition of Clementia Pharmaceuticals18.4.2019 05:00:00 CESTPressemelding

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO). Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases. The palovarotene regulatory submission for the prevention of heterotopic ossification (HO) in patients with FOP in the U.S.

Sartorius Starts off Fiscal 2019 with a Strong First Quarter18.4.2019 05:00:00 CESTPressemelding

Sartorius, a leading international partner of biopharmaceutical research and the industry, started off fiscal 2019 with substantial double-digit growth in order intake, sales revenue and earnings. Consolidated first-quarter sales revenue rose in constant currencies by 16.8% to 435.7 million (reported: +19.4%); order intake increased 16.6% to 482.8 million euros (reported: +19.3%). Sartorius’ underlying EBITDA1) surged 28.7% to 114.0 million euros. Its respective underlying EBITDA margin for the first three months of 2019 was 26.2% (Q1 2018: 24.3%), with a good half a percentage point of this increase resulting from the change in accounting rules2), as expected. Relevant net profit3) for the Group climbed 30.8% to 48.6 million euros. Earnings per ordinary share were 0.71 euros (Q1 2018: 0.54 euros); earnings per preference share, 0.72 euros (Q1 2018: 0.55 euros). “We are very pleased with our first-quarter results,” said Dr. Joachim Kreuzburg, CEO and Executive Board Chairman. “In Biopr